GlassScriptPhysician profile
Katlyn Agosta
NPI 1265043020
$857.15
in general payments reported to CMS, 2019-2025
18 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.88 · 2022: $119 · 2023: $333 · 2024: $139 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.47 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $130.30 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Lilly USA, LLC | $120.48 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Medtronic, INC. | $75.69 | 2021-2023 | Interstim |
| Sanofi Pasteur INC. | $75.06 | 2023 | |
| Janssen Scientific Affairs, LLC | $62.77 | 2023 | Xarelto |
| Pfizer INC. | $53.25 | 2022-2024 | |
| Corium, LLC | $47.39 | 2022-2023 | Azstarys |
| Mannkind Corporation | $42.50 | 2025 | |
| Exact Sciences Corporation | $39.47 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $39.47 | 2023 | Farxiga |
| Glaxosmithkline, LLC. | $36.45 | 2023-2025 | Bexsero, Shingrix |
| Dynavax Technologies Corporation | $25.67 | 2023 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $23.38 | 2024 | Rexulti |
| Novo Nordisk INC | $23.31 | 2022 | |
| Insulet Corporation | $19.26 | 2025 | Omnipod |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.33 | 2025 | Repatha |
| Merck Sharp & Dohme LLC | $14.70 | 2023 | Gardasil 9, Vaxelis, M-M-R II |
| Vbi Vaccine (Delaware) INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katlyn Agosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.